Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated June 29, 2020, reports on the 2020 Annual and Extraordinary General Meeting of Shareholders held by Enlivex Therapeutics Ltd. on June 24, 2020. The Company is organized under the laws of Israel and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Management presented a brief description of the Company's financial condition and current activities at the meeting, but these details are not included in this report. The Company's Annual Report and financial statements for the year ended December 31, 2019, were discussed at the meeting.
Material Changes
No material financial changes versus prior periods are detailed in this document. The filing focuses on corporate governance resolutions approved by shareholders.
Corporate Actions and Governance
- Board Re-election: Shareholders re-elected Shai Novik, Abraham Havron, Gil Hart, Baruch Halpert, Michel Habib, Sangwoo Lee, and Bernhard Kirschbaum to the Board of Directors.
- Compensation and Agreements: Approved an amendment to the chairman agreement with A.S. Novik and an amended and restated Compensation Policy for Executives and Directors.
- Indemnification: Approved a form of Indemnification Agreement for current and future Office Holders.
- Auditor Reappointment: Reappointed BKR Yarel & Partners CPA as auditors for the year ending December 31, 2020, authorizing the Audit Committee to fix their compensation.
Key Facts for Investor Verification
- Verify the specific terms of the amended chairman agreement with A.S. Novik in the Proxy Statement (Exhibit 99.1).
- Review the full Annual Report for the year ended December 31, 2019, for detailed financial performance data not included in this summary.
- Confirm the scope of services and compensation for the reappointed auditors, BKR Yarel & Partners CPA.
- Examine the amended Compensation Policy for Executives and Directors for changes to executive pay structures.